Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Cleveland, Ohio 44106


RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Pemetrexed disodium may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. It is not yet known whether gemcitabine is more effective with or without pemetrexed disodium in treating pancreatic cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of gemcitabine combined with pemetrexed disodium to that of gemcitabine alone in treating patients who have unresectable stage II, stage III, or stage IV pancreatic cancer.

Study summary:

OBJECTIVES: - Compare the overall survival of patients with stage II, III, or IV unresectable pancreatic cancer treated with gemcitabine with or without pemetrexed disodium. - Compare the progression-free survival of patients treated with these regimens. - Compare the time to treatment failure and duration of response in patients treated with these regimens. - Compare tumor response rate in patients treated with these regimens. - Compare the effects of these regimens on health-related quality of life in these patients. - Compare the toxic effects of these regimens in these patients. OUTLINE: This is a randomized, open-label, parallel, multicenter study. Patients are stratified according to baseline ECOG performance status (0-1 vs 2), disease stage (II or III vs IV), baseline homocysteine level (at least 12 µmol/L vs less than 12 µmol/L), and participating center. Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients receive gemcitabine IV over 30-60 minutes on days 1 and 8 and pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients also receive oral folic acid and cyanocobalamin intramuscularly every 9 weeks beginning 1-2 weeks before day 1 and continuing until 3 weeks after end of study therapy. - Arm II: Patients receive gemcitabine IV over 30-60 minutes on days 1, 8, and 15. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline, at the end of each course, and then every 3 months thereafter. Patients are followed every 3 months. PROJECTED ACCRUAL: A total of 520 patients (260 per treatment arm) will be accrued for this study.


DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed adenocarcinoma of the pancreas - Stage II, III, or IV disease that is not amenable to resection with curative intent - At least 1 bidimensionally measurable lesion with clearly defined margins by CT scan or MRI or by palpation with both diameters at least 2 cm - No clinically significant third-space fluid collection (e.g., ascites or pleural effusions) NOTE: Fluid collections may be drained - No documented brain metastases PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-2 Life expectancy - At least 12 weeks Hematopoietic - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 - Hemoglobin at least 9 g/dL Hepatic - Bilirubin no greater than 1.5 times upper limit of normal (ULN) - AST/ALT no greater than 3 times ULN (5 times ULN if liver metastases present) - Alkaline phosphatase no greater than 3 times ULN (5 times ULN if liver metastases present) - Endoscopic or radiologic stenting allowed for biliary obstructions (bilirubin must meet study requirements and AST/ALT and alkaline phosphatase must be no greater than 5 times ULN) Renal - Creatinine clearance at least 45 mL/min Cardiovascular - No unstable angina pectoris Pulmonary - See Disease Characteristics Other - No other malignancy within the past 5 years except carcinoma in situ of the cervix or adequately treated nonmelanoma skin cancer - No active infection - No other serious concurrent systemic disorders that would preclude study - No uncontrolled diabetes mellitus - No weight loss of 10% or more within the past 6 weeks - No inability or unwillingness to take folic acid or vitamin B12 supplementation - Not pregnant or nursing - Fertile patients must use effective contraception during and for 3 months after study PRIOR CONCURRENT THERAPY: Biologic therapy - No prior immunotherapy - No prior biological therapy for pancreatic cancer - No concurrent immunotherapy - No concurrent routine colony-stimulating factors - No concurrent stimulators of thrombopoiesis Chemotherapy - No prior chemotherapy for pancreatic cancer - No prior fluorouracil for pancreatic cancer (including as a radiosensitizer) - No other concurrent chemotherapy Endocrine therapy - No prior hormonal therapy for pancreatic cancer - No concurrent hormonal therapy for cancer Radiotherapy - No prior radiation to whole pelvis - Prior radiotherapy to less than 25% of bone marrow allowed - At least 4 weeks since prior radiotherapy and recovered - Concurrent palliative radiotherapy for small, painful metastases allowed Surgery - No concurrent surgery for cancer Other - At least 30 days since prior investigational agents or devices - No other concurrent experimental medications (except thymidine) - No other concurrent antitumor therapy - No concurrent aspirin, salicylates, or other nonsteroidal anti-inflammatory drugs for 2-5 days before, during, and for 2 days after each dose of pemetrexed disodium



Primary Contact:

Study Chair
Joanna M. Brell, MD
Case Comprehensive Cancer Center

Backup Contact:


Location Contact:

Cleveland, Ohio 44106
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.